Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin glargine/lixisenatide fixed-ratio combination versus insulin glargine in adults with type 2 diabetes mellitus
2013-003132-79Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in type 2 diabetes mellitus (T2DM) comparing Insulin glargine/lixisenatide fixed-ratio combination with Insulin glargine comparator (2 arms). Primary endpoint: Change in HbA1c from baseline. Started Dec 2013; status: completed.
02
Drugs
insulin glarginelixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-003132-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003132-79.